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Family historyA positive family history (FH) raises the risk for late-onset Alzheimer3s disease though, other than the known risk
conferred by apolipoprotein ε4 (ApoE4), much of the genetic variance remains unexplained.We examined the ef-
fect of family history on longitudinal regional brain atrophy rates in 184 subjects (42% FH+,mean age 79.9) with
mild cognitive impairment (MCI) enrolled in a national biomarker study. An automated image analysis method
was applied to T1-weighted MR images to measure atrophy rates for 20 cortical and subcortical regions. Mixed-
effects linear regression models incorporating repeated-measures to control for within-subject variation over
multiple time points tested the effect of FH over a follow-up of up to 48 months. Most of the 20 regions showed
signiﬁcant atrophy over time. Adjusting for age and gender, subjectswith a positive FHhad greater atrophy of the
amygdala (p b 0.01), entorhinal cortex (p b 0.01), hippocampus (p b 0.053) and cortical gray matter (p b 0.009).
However, when E4 genotype was added as a covariate, none of the FH effects remained signiﬁcant. Analyses by
ApoE genotype showed that the effect of FH on amygdala atrophy rates was numerically greater in ε3 homozy-
gotes than in E4 carriers, but this differencewas not signiﬁcant. FH+subjects had numerically greater 4-year cog-
nitive decline and conversion rates than FH− subjects but the difference was not statistically signiﬁcant after
adjusting for ApoE and other variables. We conclude that a positive family history of AD may inﬂuence cortical
and temporal lobe atrophy in subjectswithmild cognitive impairment, but it does not have a signiﬁcant addition-
al effect beyond the known effect of the E4 genotype.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Genetic factors signiﬁcantly inﬂuence late-onset Alzheimer3s disease
(AD) though by some estimates 30–65% of the genetic variance remains
unexplained by the four established AD genes (Tanzi, 2012;Mahley and
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. This is an open access article under(ε4) allele, account for most of the known heritability of late-onset AD
(Tanzi, 2012). A positive family history is a risk factor for late-onset
AD (Tanzi, 2012; Cupples, 2004; Silverman, 1994), with studies indicat-
ing a 2–4-fold larger risk in ﬁrst-degree relatives. Some of this risk is
additive to the known risk conferred by the ApoE gene suggesting a
missing heritability. Currently, in routine practice, clinicians still rely
on a simple “yes/no”measure of self-reported FH status to evaluate sub-
jects at risk — hence, studies examining the effect of FH on biomarker
phenotypes may improve the interpretation of biomarker tests and
the counseling of at risk subjects.
Several studies have examined the effect of FH on biomarkers
(Lampert, 2013; Honea, 2011; Xiong, 2011; Andrawis, 2012; Okonkwo,
2012). For example, several cross-sectional studies in mild cognitive im-
pairment or normal subjects report that ﬁrst-degree relatives have a
higher prevalence of abnormal cerebrospinal ﬂuid beta-amyloid and/or
tau phenotypes, even after accounting for the known effects of age and
ApoE4 (Lampert, 2013; Xiong, 2011). One of these studies also estimated
that the unexplained genetic heritability in FH (for an effect on beta-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2013).
Prior studies have also examined the effect of FH on hippocampal
volume (Lampert, 2013; Honea, 2011; Andrawis, 2012; Okonkwo,
2012). In a prior cross-sectional study of normal, MCI, and AD subjects,
we failed to ﬁnd an effect of FH on hippocampal volume (Lampert,
2013). However, in another study of normal subjects derived from the
KU Brain Aging Project, maternal FH was reported to inﬂuence 2-year
volume loss in the precuneus, parahippocampal andhippocampus inde-
pendent of ApoE4 (Honea, 2011). Supporting this was another 1-year
multisite study, which found thatmaternal (but not paternal family his-
tory) was associated with increased hippocampal atrophy in MCI sub-
jects but not in normal or AD subjects (Andrawis, 2012). However,
another 4-year study of middle aged normals, in the Wisconsin Aging
study, found that FH status predicted greater atrophy only within a
posterior sub-region of the hippocampus but not in other gray matter
regions, and that therewas no effect ofmaternal versus paternal history
(Okonkwo, 2012). Reasons for discrepancy may be differences in inclu-
sion criteria, sample size, follow-up duration, image analyses, and co-
variates used.
The Alzheimer3s Disease Neuroimaging Initiative (ADNI) is a highly
successful national longitudinal biomarker research study (Weiner,
2010) and as such it is ideal formore deﬁnitive testing of preliminary re-
sults generated by single site studies. Stringent subject selection criteria,
serial MRI scans using qualiﬁed scanners and phantoms, and standard-
ized centralMR image analyses are someof themany strengths of ADNI.
The goal of this present analysiswas to useADNI data to test the effect of
FH on longitudinal atrophy rates (up to 48 months) of 20 brain regions
in subjects with MCI. We decided to focus on subjects with mild cogni-
tive impairment for three reasons: ADNI included twice as many MCI
subjects as controls; MCI subjects are at greater risk for progression to
AD than normal controls; MCI subjects have a greater rate of atrophy
than normal controls. Hence, the MCI group offered greater power for
testing our hypotheses andwas alsomore relevant to the type of subject
seen in routine clinical practice. Our primary hypothesis was that a
positive FH would be associated with greater rate of atrophy in brain
regions known to degenerate early in AD such as the hippocampus,
amygdala, entorhinal cortex, and cortical gray matter.
2. Materials and methods
2.1. Subjects
Data used in the preparation of this article were obtained from the
Alzheimer3s Disease Neuroimaging Initiative (ADNI-1) database
(http://adni.loni.usc.edu) (Weiner, 2010). The ADNI was launched in
2003 by the National Institute on Aging (NIA), the National Institute of
Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Ad-
ministration (FDA), private pharmaceutical companies, and nonproﬁt
organizations, as a 5-year public–private partnership. The primary
goal of ADNI has been to test whether serial magnetic resonance imag-
ing (MRI), positron emission tomography (PET), other biological
markers, and clinical and neuropsychological assessment can be com-
bined to measure the progression of mild cognitive impairment and
early Alzheimer3s disease (AD). Determination of sensitive and speciﬁc
markers of very early AD progression is intended to aid researchers
and clinicians to develop new treatments and monitor their effective-
ness, as well as lessen the time and cost of clinical trials.
The Principal Investigator of this initiative isMichaelW.Weiner,MD,
VAMedical Center and University of California— San Francisco. ADNI is
the result of efforts of many co-investigators from a broad range of
academic institutions and private corporations, and subjects have
been recruited from over 50 sites across the U.S. and Canada. The initial
goal of ADNI was to recruit 800 subjects but ADNI has been followed by
ADNI-GO and ADNI-2. To date these three protocols have recruited over
1500 adults, ages 55–90, to participate in the research, consisting ofcognitively normal older individuals, people with early or late MCI,
and people with early AD. The follow-up duration of each group is spec-
iﬁed in the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects origi-
nally recruited for ADNI-1 and ADNI-GO had the option to be followed
in ADNI-2. For up-to-date information, see http://www.adni-info.org.
For additional details readers can also refer to the ADNI-1 Procedures
manual (ADNI, 2013; Alzheimer3s Disease Neuroimaging Initiative,
2013).
2.2. Selection criteria
Only subjects with a baseline diagnosis of MCI were eligible for this
study. Additionally, subjects selected for analysis were required to have
data for all of the following parameters: baseline age, race, gender, and
years of education; baseline Mini-Mental State Examination (MMSE)
score; ApoE genotyping results; and family history status of AD. Subjects
also needed initial visit 1.5 T MR scans analyzed centrally by FreeSurfer
software (v.4.4) to derive cortical thickness and sub-cortical volume
data; and a minimum of two other follow-up MRI time points (6, 12,
18, 24, 36, or 48 months from baseline) with centrally FreeSurfer ana-
lyzed MRI data. A total of 184 MCI subjects in ADNI-1 were included.
2.3. MCI criteria
To be classiﬁed as MCI in ADNI a subject needed an inclusive MMSE
score between 24 and 30, subjective memory complaint, objective evi-
dence of impaired memory calculated by scores of the Wechsler Mem-
ory Scale Logical Memory II adjusted for education, a score of 0.5 on the
Global CDR, absence of signiﬁcant confounding conditions such as
current major depression, normal or near normal daily activities, and
absence of clinical dementia. For a detailed list of all selection criteria
readers are referred to the ADNI-1 Procedures manual (ADNI, 2013).
2.4. Family history criteria
FH data was collected by an interview with the subject and their
study partner regarding the presence of AD in the subject3s parents
and siblings. A control typically self-reported while the study partner
was the main source of information for memory-impaired subjects. A
positive family history (FH+) was characterized as having a parent or
sibling, living or deceased, who had been reported as diagnosed with
AD. A negative family history (FH−) meant having no reported parents
or siblings with a history of AD. ADNI participants with uncertain family
history status were excluded from the analysis.
2.5. ApoE genotyping
ApoE allele genotyping of all subjectswas executed usingDNAextract-
ed fromperipheral blood cells with details given elsewhere (ADNI, 2013).
2.6. MR imaging acquisition
ADNI used 1.5 T MP-RAGE T1-weighted MR images that were later
pre-processed and corrected for nonlinearity via “GradWarp.” The
scans were implemented using a standardized ADNI protocol adjusted
for use at each speciﬁc collection site and then underwent scaling and
vetting to meet quality control criteria. For more detailed information
regarding the speciﬁc MR acquisition protocols and control methods
used please see http://adni.loni.usc.edu.
2.7. MR cortical thickness and volumetric methods
FreeSurfer image analysis was used for derivation of cortical thickness
and volumetric segmentation.We selected 20brain regions of interest, in-
cluding 4 regions known to atrophy in early AD (hippocampus, amygdala,
cortical gray matter volume, and entorhinal cortex) as well as other re-
gions of exploratory interest. Speciﬁc details about these techniques
Table 1
Baseline characteristics of FH+ versus FH−MCI subjects in ADNI.
Attribute FH− FH+ p-Value
n 106 78
Age (mean) 80.99 78.9 0.05
M/F ratio 1.58 1.28 0.56
Education (years) 15.61 15.48 0.76
MMSE 27.22 27.15 0.79
MRI follow up time (months) 27.8 29.5 0.25
ApoE4 % 0.41 0.65 0.002
MCI=mild cognitive impairment; FH- indicates those subjectswithout a family history of
AD in a ﬁrst degree relative; FH+ indicates those subjects with a positive family history;
M/F ratio is male/female ration; MMSE is Mini-Mental State Exam; ApoE4% is percent in
each group who carry the ApoE4 allele; ADNI is the Alzheimer’s Disease Neuroimaging
Initiative. Refer to text for details of selection criteria.
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2002; Sled et al., 1998; Fischl et al., 2001; Fischl et al., 1999; Fischl and
Dale, 2000; Han, 2006; Hostage et al., 2014). Morphometric procedures
using FreeSurfer have been shown to demonstrate good test–retest
reliability (Han, 2006). For more information please see http://adni.loni.
usc.edu.
2.8. Statistical analyses
For each region of the brain, the longitudinal variation in thickness/
volume was modeled as a log-linear function of time and other subject
information. Firstly, we used gender, age and family history status:
logðVi jðtÞÞ ¼ μ j þ ai þ βa jAgeþ α F j þ α FH j
β jt þ bit þ β F jt þ β FH jt þ εi jt: ð1:1Þ
The response Vij(t) is the thickness/volume in the jth region of the
brain, j= 1, 2,…, 20 for the ith subject, i= 1,…, 184, measured at the
tth time point, t = 0, 6, 12, 18, 24, 36, or 48 months. The terms in the
model include μj, the baseline thickness volume, measured at time 0,
for a 75 year old male subject with no family history of Alzheimer3s.
The baseline subject represents the most common subject characteris-
tics in the study, and the reference age represents the ﬁrst quartile of
ages in the study. There is also a subject speciﬁc random effect, ai, as-
sumed to have a Gaussian distribution with 0 mean and SD σa2. This
term accounts for subject speciﬁc variation in the baseline brain volume,
due to factors such as difference in intra-cranial brain volume. In addi-
tion, we have a linear effect of age (centered at 75), with coefﬁcient
βaj, an additional effect for females, αFj, as well as an effect of positive
family history, αFHj. The aforementioned effects are all at t=0 and spe-
ciﬁc to region j. Next, wemodel atrophy (or volume increase) as a linear
function in time, decomposed into effects of the demographic variables:
ﬁrstly, βj is the baseline rate of atrophy, corresponding to the baseline
subject described above. There is also a subject speciﬁc random rate of
atrophy, bi, assumed to have a Gaussian distribution with 0 mean and
SD σb2. This term allows the rate of atrophy to vary across subjects, as a
proxy for terms not explicitly included in the model, such as genetic
and lifestyle factors. We also have an additional atrophy effect for
females, βFj, as well as an atrophy effect of positive family history, αFHj.
Finally, εijt is a random measurement error, assumed to have a zero
mean Gaussian distribution with SD σ2. The brain volumes Vij(t) were
log transformed to ensure that the distribution of the estimated error
terms (residuals) of the model better conformed to the assumption of
Gaussianity.
We also used a secondmodel, where additional genetic information
was incorporated:
logðVi jðtÞÞ ¼ μ j þ ai j þ βa jAgeþ α F j þ α FH j þ αE4 jþ
β jt þ bi jt þ β F jt þ β FH jt þþβE4 jt þ εi jt: ð1:2Þ
In model (1.2), the common terms represent the same things as in
model (1.1), except that the baseline subject additionally possesses
the ApoE 3/3 allele. The term αE4j denotes the additional baseline effect
of the ApoE 4+ allele, while βE4j denotes the additional atrophy effect of
the ApoE 4+ allele. Both models were ﬁt separately to data from each
region of the brain, using restrictedmaximum likelihood (REML), as im-
plemented in the nmle package [Pinheiro et al. Linear and Nonlinear
Mixed Effects Models. R package version 3.1-113, 2013] in the R com-
puting platform (http://www.r-project.org).
Our a priori primary hypothesis regions included those well known
to atrophy in early AD such as the hippocampus, amygdala, entorhinalcortex and cortical gray matter. We applied a Bonferroni correction to
exploratory analyses of all other regions.
3. Results
Baseline features of the sample are summarized in Table 1. 42% of the
sample had a positive FH. Therewere no signiﬁcant differences by FH for
gender, years of education, orMMSE score. Therewas a difference in age
(p = 0.05), and as expected there was an overrepresentation of the
ApoE4 allele in FH+ subjects (p = 0.002). Total follow-up was up
to 48 months, and the mean follow-up time for the FH− group
(27.8 months) was not signiﬁcantly different from the FH+ group
(29.5 months, p b 0.25).
3.1. Effect of FH after adjusting for age and gender
As shown in the ﬁrst three columns in Table 2, most brain regions
showed a signiﬁcant atrophy over time (i.e. base rate). The effect of
positive FH is shown in the last three columns. Adjusting for age and
gender, subjects with a positive FH had greater atrophy of the cerebral
cortex (p b 0.009), amygdala (p b 0.01), entorhinal cortex (p b 0.01)
and hippocampus (p b 0.053).
3.2. Effect of FH after adjusting for age, gender and ApoE
Table 3 depicts the estimated effects and signiﬁcance of ApoE ε4+ and
FHon longitudinal atrophy rates. In thismodel, some15 regions showed a
signiﬁcant ApoE4+ effect including all the predicted primary regions
(such as the hippocampus, amygdala, entorhinal cortex and cerebral cor-
tex). However, none of the primary predicted regions showed a signiﬁ-
cant FH effect in this model and the atrophy rate attributable to FH was
considerably smaller than that attributable toApoE4. Fig. 1 compares atro-
phy rates due to ApoE4+ versus those due to FH+— it shows that most
FH effects are small relative to ApoE4+ effects, as evidenced by the
wider spread of ApoE4+ effects while most FH+ rates remained close
to zero.
3.3. Effect of FH on atrophy rates in ApoE ε3 homozygotes
Table 4 summarizes the model when ﬁt to only ε3 homozygotes —
there was no signiﬁcant FH effect on any predicted region and effect
sizes (Cohen3s D) ranged from 0.05 to 0.22. For example, the FH effect
size on the amygdala atrophy rate was−0.17 (p b 0.14). Exploratory
analyses comparing the effect of FH in ApoE ε4+ versus ε 3/3 subjects
showed that some regions exhibit a slightly greater FH effect on atrophy
in the ε 3/3 group (e.g. amygdala) whereas some other regions have a
greater FH effect in the ε4+ group (e.g. hippocampus) but none of
these were statistically different.
Table 2
Effect of family history on 4-year atrophy rates.
Primary regions Baseline rate of atrophy Baseline SE Baseline
p-value
FH rate FH SE FH p-value
Hippocampus.total.vol −0.024 0.003 b0.0001 −0.004 0.002 0.053
Amygdala.total.vol −0.004 0.006 0.515 −0.01 0.004 0.011
Entorhinal.cortex.TA −0.02 0.004 b0.0001 −0.007 0.003 0.01
Cerebral.cortex.total.vol −0.011 0.002 b0.0001 −0.003 0.001 0.009
Exploratory regions
Parahippocampal.TA −0.016 0.004 b0.0001 −0.004 0.002 0.096
Pericalcarine.TA −0.001 0.003 0.829 −0.002 0.002 0.263
Postcentral.TA −0.009 0.003 0.002 0.002 0.002 0.239
posterior.cingulate.TA −0.009 0.003 0.004 −0.001 0.002 0.508
Precentral.TA −0.015 0.004 0.001 0.002 0.003 0.39
Precuneus.TA −0.007 0.003 0.026 −0.002 0.002 0.224
Superior.Parietal.TA −0.006 0.003 0.066 −0.002 0.002 0.329
Superior.temporal.TA −0.013 0.003 b0.0001 0.001 0.002 0.631
Temporal.Pole.TA −0.015 0.004 0.001 −0.001 0.003 0.665
Transverse.temporal.TA −0.007 0.005 0.134 0.005 0.003 0.127
Cerebellar.cortex.total.vol −0.011 0.003 b0.0001 −0.005 0.002 0.007
Cerebellar.WM.total.volume 0.006 0.004 0.191 0.003 0.003 0.218
Fusiform.gyrus.TA −0.007 0.003 0.016 −0.003 0.002 0.094
Inferior.parietal.TA −0.007 0.003 0.035 −0.002 0.002 0.256
Inferior.temporal.TA −0.009 0.003 0.002 −0.003 0.002 0.117
Middle.temporal.TA −0.009 0.003 0.003 −0.002 0.002 0.245
Base rate is the unadjusted annual rate for all MCI subjects. FH rate indicates additional effect of FH after adjusting for age and gender. Four key a priori predicted regions are listed under
“primary regions”. The estimated rate effects are in units of percent increase in log volume per year: a value of 1.00 (approximately) represents a 1% increase in volume per year. Negative
values indicate atrophy.
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Duration of follow-up available for cognition was longer than that
available for MRI scans andwe examined the baseline and last available
time point within the 4 year window. Duration of follow-up tended to
be longer in FH+ subjects (mean 43.7 months) than FH− subjects
(mean 38.5 months) (p = 0.02). FH+ subjects (57%) had numerically
higher rate of conversion from MCI to dementia than FH− subjects
(45%) but the difference was not statistically signiﬁcant. FH+ subjects
(mean 7 points ±10) had numerically greater decline in cognitionTable 3
Effect of FH on atrophy rates after adjusting for ApoE4.






















ApoE4 rate is the additional rate for E4 positive subjects. A negative sign indicates greater atroph
ApoE4. ApoE4 rates (of atrophy) for the amygdala, hippocampus and entorhinal cortex are sever
volume per year: a value of 1.00 (approximately) represents a 1% increase in volume per year.(ADAS-Cog) than FH− subjects (mean 5.7 points ±9) but the FH effect
wasnot statistically signiﬁcant in amultivariatemodelwith age, gender,
education, baseline cognition, E4 and time. Gender andApoE4 genotype
(p = 0.313) were signiﬁcant in this model.
4. Discussion
To our knowledge, this is the ﬁrst national long-term (up to
48months) examination of the effects of FH on atrophy rates ofmultiple
regions inMCI subjects at risk for future AD.We found that a positive FHApoE4+
p-value
FH rate FH SE FH p-value
b0.00001 −0.001 0.002 0.71
b0.00001 −0.006 0.004 0.12
b0.00001 −0.003 0.002 0.28
b0.00001 −0.002 0.001 0.2
b0.00001 −0.001 0.002 0.65
0.31028 −0.002 0.002 0.2
0.00679 0.003 0.002 0.1
0.00001 0 0.002 0.89
0.00061 0.004 0.003 0.14
b0.00001 −0.001 0.002 0.73
b0.00001 0 0.002 0.88
b0.00001 0.003 0.002 0.12
b0.00001 0.002 0.003 0.58
0.58824 0.005 0.003 0.11
0.31333 −0.005 0.002 0.01
0.61001 0.003 0.003 0.26
b0.00001 −0.001 0.002 0.51
b0.00001 0 0.002 0.88
b0.00001 −0.001 0.002 0.69
b0.00001 0 0.002 0.95
y over time. FH rate indicates the additional effect of FH after adjusting for age, gender and
al fold greater than the FH rates. The estimated rates are in units of percent increase in log
Fig. 1. Comparison of atrophy rates due to ApoE4+versus FH+. The diagonal line denotes
equality of rates. Note that most FH+ rates (horizontal dotted line) are close to 0, while
ApoE4+ rates have a wider spread from zero (vertical dotted line). Most FH effects are
small relative to ApoE4+ effects. Negative values indicate atrophy.
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(amygdala, hippocampus, and entorhinal cortex) plus cortical gray vol-
ume inMCI but that the residual FH effect on atrophy rate, after covary-
ing for ApoE E4, was no longer signiﬁcant for any brain structure. The
residual FH effect was also substantially smaller than that of the ApoE4
effect. We also found that in the subset of ApoE3 homozygotes, there
was no signiﬁcant FH effect on any key structure.
These data suggest that any missing heritability within FH (other
than ApoE4) for explaining atrophy rate in MCI subjects is likely to be
quite small and nonsigniﬁcant. Lastly, given the large size of the main
E4 effect relative to themain FH effect inMCI subjects, our data suggests
that much of the E4 effect may not be containedwholly in the FH effect.
There appeared to be a weak interaction between ApoE status and FH in
that the effect of FH on amygdala atrophy rates seemed larger in E3 ho-
mozygotes than E4 carriers, but this too was not signiﬁcant.
Prior studies of FH effects on CSF [reviewed in Lampert, 2013] and
FDG-PET [reviewed in Mosconi, 2007] biomarkers have generally
found consistent changes. However, prior studies of FH effects onTable 4
Effect of FH on atrophy rates in ApoE 3/3 homozygotes.
Primary regions FH rate Cohen3s D for FH effect FH p-value
Hippocampus.total.vol 0.002 0.07 0.54939
Amygdala.Total.Vol −0.009 −0.17 0.14095
Entorhinal.cortex.TA −0.001 −0.04 0.70974
Cerebral.cortex.total.vol 0.001 0.04 0.72922
Exploratory regions
Parahippocampal.TA 0.002 0.06 0.61137
Pericalcarine.TA −0.005 −0.22 0.0535
Postcentral.TA −0.001 −0.03 0.77311
Posterior.cingulate.TA 0.002 0.1 0.3911
Precentral.TA −0.004 −0.12 0.29272
Precuneus.TA 0.002 0.1 0.39153
Superior.parietal.TA −0.001 −0.04 0.72119
Superior.temporal.TA 0.002 0.09 0.4295
Temporal.pole.TA −0.002 −0.06 0.57661
Transverse.temporal.TA 0.005 0.13 0.26851
Cerebellar.cortex.total.vol 0.001 0.05 0.68839
Cerebellar.WM.total.volume −0.002 −0.06 0.60951
Fusiform.gyrus.TA −0.003 −0.11 0.35543
Inferior.parietal.TA 0 0.01 0.9105
Inferior.temporal.TA −0.003 −0.13 0.27452
Middle.temporal.TA −0.001 −0.06 0.59783
FH rate is the additional effect of FH after adjusting for age and gender. The estimated rate
effects are in units of percent increase in log volume per year: a value of 1.00 (approxi-
mately) represents a 1% increase in volume per year. Negative values indicate atrophy.
The amygdala is the only region that comes close to signiﬁcance among the predicted
regions.longitudinal hippocampal atrophy rates have yielded potentially con-
ﬂicting ﬁndings (Honea, 2011; Andrawis, 2012; Okonkwo, 2012).
Honea (2011) found a positive effect for maternal FH, independent of
E4 status, on 2-year hippocampal atrophy rate in normal controls —
and proposed that this supported the mitochondrial hypothesis of AD.
Andrawis (2012) did notﬁnd a signiﬁcant effect of FH on 1-year atrophy
rates in normal controls or AD patients but did ﬁnd an effect for mater-
nal FH inMCI subjects. Yet another study of normal middle-aged adults,
by Okonkwo (2012), found a FH effect on atrophy only in a posterior
subregion of the hippocampus and only in E4− subjects — there was
no FH effect in E4+ subjects. In addition, Okonkwo et al. foundno signif-
icant difference between maternal and paternal FH on atrophy rate
(Okonkwo, 2012). The follow-up in Okonkwo3s study was 4-years and
longer than prior studies but their controls were younger. These studies
relied on just 2 MRI scans (baseline and follow-up) to extract atrophy
rates.
Our study extends these data by examiningMCI subjects over a lon-
ger follow-up period (3 MRI scans and up to 48 month follow-up) and
by examining multiple brain regions. The use of 3 MRI scans over this
period may have allowed for a more accurate estimate of the slope of
change than in prior studies. Further, our examination of 20 different
brain regions allowed us to examine changes in regions associated
with cognitive brain circuits known to be affected early in AD. Overall,
our data do not support a signiﬁcant residual (after covarying for ApoE
status) FH effect on rates of atrophy of any key brain region. Since we
did not examine maternal versus paternal FH, our study cannot settle
questions relating to the mitochondrial hypothesis.
A strength of this current study is the use of a relatively large sample
of carefully selectedMCI subjects, data collected in a standardizedman-
ner from many sites across the country, multiple imaging time points,
and relatively long duration of follow-up. Nonetheless, there are still
some limitations. FH statuswas ascertained via interviewswith the sub-
jects and their study partners, so it is possible that there may have been
a reporter bias (for example, some respondents may not know the dif-
ference between AD and dementia). That said, our ﬁndings are still rel-
evant because FH is collected by simple history in most clinics and
biomarker research studies. We studied only MCI subjects and did not
examine interactions of FH with amyloid or tau phenotypes. Prior stud-
ies have shown that amyloid positivity may be linked to E4 status
[reviewed in Lampert, 2013] and accelerated atrophy [reviewed in
Honea, 2011], and so it is conceivable that there may also be an interac-
tion of amyloid status with FH. We also did not analyze subregions of
the hippocampus and hence could not directly test ﬁndings that FH
might affect only speciﬁc subregions (Okonkwo, 2012). We also did
not examine the effect of FH on glucosemetabolic status, anothermark-
er that has been linked to FH (Mosconi, 2007). Thus, our ﬁndings cannot
be generalized to other biomarkers or other diagnostic groups. As stated
earlier, we did not testmaternal versus paternal FH sincewedid not col-
lect that data. Likewise, we were unable to test parental versus sibling
FH as there is a vast majority of patients with an affected parent (n =
51 parental, n = 9 both, n = 18 sibling; 77% parental) and therefore
not enough power to separate the two. Thus, our study must be
interpreted within these potential limitations.
Future directions of this study should include further analysis to de-
termine if there are other genetic factors (e.g. whole genome data) in
addition to ApoE4 that predict atrophy rates in brain regions susceptible
to AD as well as studies examining the effect of FH on multiple bio-
markers (MRI, CSF, PET) over longer periods of time. Since FH has
been linked to beta-amyloid positivity and amyloid deposition in turn
has been linked to atrophy, future studies should examine FH effects
in healthy controls who are amyloid positive (i.e., preclinical AD).
Only a subset of ADNI-1 subjects had CSF or amyloid PET data. ADNI2,
where every subject underwent ﬂorbetapir PET, will allow for a better
test of this theory in the near future. Such informationmay serve to fur-
ther improve personalized testing and drug development for at-risk
patients.
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Supplementary materials
Classiﬁcation, clinical diagnosis, and ApoE genotyping
Speciﬁc exclusion criteria for the ADNI study included: presence of
other signiﬁcant neurologic disease; baseline MR scans showing evi-
dence of infection, infarction, or other focal lesion or multiple lacunes;
and thosewith pacemakers, aneurysm clips or other devices which pre-
vent them from receiving MR imaging. In addition, subjects wereexcluded due to the presence of major depression, psychotic features,
alcohol/substance abuse or dependence in previous 2 years; signiﬁcant
medical illness or laboratory abnormalities (B12, RPR, TFTs) that might
have interferedwith the study; residence in a skilled nursing facility; or
current use of warfarin or certain other psychoactive medications.
MR cortical thickness and volume derivations
Brieﬂy, this processing includes motion correction and averaging
(Tanzi, 2012) of multiple volumetric T1 weighted images (when
more than one is available), removal of nonbrain tissue using a hybrid
watershed/surface deformation procedure (Mahley and Rall, 2000), auto-
mated Talairach transformation, and segmentation of the subcortical
white matter and deep gray matter volumetric structures (including the
hippocampus, amygdala, caudate, putamen, and ventricles) (Cupples,
2004). It also involves intensity normalization (Silverman, 1994), tessella-
tion of the gray matter white matter boundary, automated topology cor-
rection (Lampert, 2013; Honea, 2011) and surface deformation following
intensity gradients to optimally place the gray/white and gray/cerebro-
spinalﬂuid borders at the locationwhere the greatest shift in intensity de-
ﬁnes the transition to the other tissue class (Xiong, 2011; Andrawis, 2012;
Okonkwo, 2012). Once the cortical models are complete, a number of de-
formable procedures can be performed for further data processing and
analysis including surface inﬂation (Weiner, 2010), registration to a
spherical atlas which utilized individual cortical folding patterns to
match cortical geometry across subjects (ADNI, 2013), parcellation of
the cerebral cortex into units based on gyral and sulcal structures
(Alzheimer3s Disease Neuroimaging Initiative, 2013; Ségonne, 2004)
and creationof a variety of surface based data includingmaps of curvature
and sulcal depth. Thismethoduses both intensity and continuity informa-
tion from the entire three dimensional MR volume in segmentation and
deformation procedures to produce representations of cortical thickness,
calculated as the closest distance from the gray/white boundary to the
gray/CSF boundary at each vertex on the tessellated surface (Fischl,
2002). Themaps are created using spatial intensity gradients across tissue
classes and are therefore not simply reliant on absolute signal intensity.
The maps produced are not restricted to the voxel resolution of the orig-
inal data thus are capable of detecting sub-millimeter differences be-
tween groups. Procedures for the measurement of cortical thickness
have been validated against histological analysis (Sled et al., 1998) and
manual measurements (Fischl et al., 2001; Fischl et al., 1999). FreeSurfer
morphometric procedures have been demonstrated to show good test–
retest reliability across scanner manufacturers and across ﬁeld strengths
(Fischl and Dale, 2000; Han, 2006).
Longitudinal processing has been performed with the longitudinal
stream in FreeSurfer, where an unbiased within-subject template
space and average image (Hostage, et al., 2014) is created using robust,
inverse consistent registration (Cupples, 2004). Information from this
subject template is used to initialize the longitudinal image processing
in several locations to increase repeatability and statistical power.
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